- Email: [email protected]
Correlation of risperidone levels with clinical response in schizophrenic patients
S29
Poster B. Psychopharmnca
El
B 71
Appllcatlon of lexilium in outpatient practice
V. Sernke, I. Kupriyanova, S. Maltseva, V. Lebedeva. Mental Health Research Instirute, Sosnovy bor, Tomsk, 6340146, Russia
In clinical trial of lexilium (firm “Alcaloid A.D.“), in outpatient conditions number of the treated patients included subjects with borderline mental disorders (neuroses, neurosis similar states, psychopathies, residual organic psychopathology, 25 patients). Psychopathological symptomatology was characterised by anxious mood, preoccupation, timidity, irritability, sensation of tension decrease of intelIectual productivity, complex of vegetative manifestations. Sleep disorder was the core symptom and was expressed in disturbance of falling asleep, absence of sensation of rest. Depth of symptomatology constituted from 12 to 21 points on Hamilton Anxiety Scale. Clinical dynamics has begun to manifest itself on the 3rd day in patients with higher doses of the preparation (3.0-l.O), with doses 0.5-0.75 dynamics was observed on the 5th day of intake of the preparation. Among side effects only drowsiness and slowing down were observed in one female patient and by decrease of the preparation to 0.5 state has normalized. It has been marked that own sensation of improvement in most patients appear on the 7th-8th day of the treatment. Among the first symptoms clinical manifestations of anxiety disappear, on the 7th-14th day normalization of the sleep happens, to the 21st day ability to intellectual activity is restored. The preparation is well tolerated in outpatient practice, removes asthenic manifestations, normalizes sleep, stops anxiety and associated with it symptoms, and stabilizes vegetative manifestations. B-72 El
Qmnukcyte-colony-stlmulating factor (G-CSF) treatment of cioxapine-induced agranulocytosis
C. Leotsakou”, I. Baltathskisb, A. Giant&&, A. Kolovoub, M. Pagonib, E. Niiforakisb, G. Saroglou’, St. Theodoropoulou”. “Department of Psychiatry, bDepartment Department of Internal Athens, Greece
of Hematology and Lymphoma and ‘First Medicine, Evangelismos General Hospital,
Agranulocytosis [defined as an absolute neutrophil count (ANC)0.5X109/L on the 6th and >l.0X109/L on the 7th day of treatment. G-CSF was discontinued when ANC remained >l.0X169/L for three consecutive days. Treatment with G-CSF can dramatically shorten the duration of clozapine-induced agranulocytosis even in the most severe cases characterized by profound depression of the myeloid series in the bone marrow. Serial neutrophil count measurements in patients receiving clozapine are mandatory. Prompt administration of G-CSF if ANC
1B-73 ] Correlation of riaperidone levels with clinlcal response in schlxophmnic patients St. Theodoropoulou”, C. Leotsakou”, K. Kamtsou”, M. Asimaki”, A. Melpidoub, H. Nikolou’, N. Thalassinos”. “Departmenr of Psychiatry, bDepartment Evangelismos
of Biochemistry, and ‘Department General Hospital, Athens, Greece
of Endocrinology,
Risperidone has been in use for some time in the treatment of psychotic
patients, based primarily on data derived from short-term usage of the drug. There exists however only insuflicient information correlating levels of the medication with clinical response, extrapyramidal sideeffects (EPS) or ptolactin (PRL) levels over periods longer than 8 weeks. To assess this, we enrolled 25 DSM-IV schizophrenic patients, mainly of recent onset, in a prospective study using risperidone 6-16 mglday. Five patients dropped out because of exacerbation (n=l) or minimal improvement (n=3) of psychotic symptoms or occurrence of severe akathisia (n=l). In the 20 remaining patients (14 men, 6 women; mean age 27.127.95 years) we investigated: (1) clinical response, as estimated by Positive and Negative Syndrome Scale (PANSS). Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (C.G.I.)-Severity of Illness and Improvement and (2) EPS by Bxtrapyramidal Symptoms Rating Scale (ESRS) at baseline and at 8 and 16 weeks of treatment; (3) sum of risperidone and its metabolite, 9-OH-risperidone, plasma levels by RIA and (4) plasma PRL levels by IRMA at 8 and 16 weeks of treatment. An overall score reduction in alI scales was observed over time. Twelve patients (60%) showed clinical improvement at 8 weeks and 17 (85%) at 16 weeks (responders as defined by Kane et al., 1988). All responders required a lower daily dose than non-responders (statistically significant at p
I B-74
The antioxidant status of saliva and blood plasma in depression
A.I. L&ash, V.G. Zaika, N.P. Milutina, A.O. Kucherenko. The Depanment of Biochemistry, Rostov State University, B. Sadovay, 105, 344006. The Depamnent of Psychiatry, Rostov State Medical Vniversify, Nakhichevansci, 31, 344022, Rostov-on-Don, Russia The aim of present work is to estimate the possibility of saliva application
for the antioxidant status of depressive states. The activity of antioxidant systems was studied in the blood plasma and the saliva of 23 depressive patients (according to ICD-10: F 32 depressive episode; F 33 recurrent depressive disorders) in comparison with group of practically healthy donors (12 peoples). The total estimation of the seriousness of depression state was evaluated by Hamilton Scale (HRDS). Extracellular superoxidedismutase (SOD) activity was increased in saliva and blood plasma by 83% and 95% correspondingly, catalase activity-79% and 74%. total peroxidase activity (TPA) by 221% and 106%. Ceruloplasmine activity was increased in the saliva of depressive patients by 77%. The level of middle mass molecules (MMM) having antioxidant properties was rose by nucleotide fraction component (254 nm) as well as by peptide fraction component (280 nm). Perhaps these alterations may be regarded as partial compensation of the increase of free radical process level by 28% in saliva and by 22% in blood plasma (according to light sum of Fe*+-induced hemiluminescence). After antidepressant treatment (amitriptyline, imizin, fluoxetine, coaxil) we discovered the decrease of HDRS sum 2.5-3 times in the all studies groups of depressive patients. The positive dynamics was noted for many investigated parameters, however only cat&se activity in blood plasma and saliva; SOD activity in saliva and also the peptive fraction of MMM (280 nm) in blood plasma amounted to control values.
Poster B. Psychopharmnca
El
B 71
Appllcatlon of lexilium in outpatient practice
V. Sernke, I. Kupriyanova, S. Maltseva, V. Lebedeva. Mental Health Research Instirute, Sosnovy bor, Tomsk, 6340146, Russia
In clinical trial of lexilium (firm “Alcaloid A.D.“), in outpatient conditions number of the treated patients included subjects with borderline mental disorders (neuroses, neurosis similar states, psychopathies, residual organic psychopathology, 25 patients). Psychopathological symptomatology was characterised by anxious mood, preoccupation, timidity, irritability, sensation of tension decrease of intelIectual productivity, complex of vegetative manifestations. Sleep disorder was the core symptom and was expressed in disturbance of falling asleep, absence of sensation of rest. Depth of symptomatology constituted from 12 to 21 points on Hamilton Anxiety Scale. Clinical dynamics has begun to manifest itself on the 3rd day in patients with higher doses of the preparation (3.0-l.O), with doses 0.5-0.75 dynamics was observed on the 5th day of intake of the preparation. Among side effects only drowsiness and slowing down were observed in one female patient and by decrease of the preparation to 0.5 state has normalized. It has been marked that own sensation of improvement in most patients appear on the 7th-8th day of the treatment. Among the first symptoms clinical manifestations of anxiety disappear, on the 7th-14th day normalization of the sleep happens, to the 21st day ability to intellectual activity is restored. The preparation is well tolerated in outpatient practice, removes asthenic manifestations, normalizes sleep, stops anxiety and associated with it symptoms, and stabilizes vegetative manifestations. B-72 El
Qmnukcyte-colony-stlmulating factor (G-CSF) treatment of cioxapine-induced agranulocytosis
C. Leotsakou”, I. Baltathskisb, A. Giant&&, A. Kolovoub, M. Pagonib, E. Niiforakisb, G. Saroglou’, St. Theodoropoulou”. “Department of Psychiatry, bDepartment Department of Internal Athens, Greece
of Hematology and Lymphoma and ‘First Medicine, Evangelismos General Hospital,
Agranulocytosis [defined as an absolute neutrophil count (ANC)
1B-73 ] Correlation of riaperidone levels with clinlcal response in schlxophmnic patients St. Theodoropoulou”, C. Leotsakou”, K. Kamtsou”, M. Asimaki”, A. Melpidoub, H. Nikolou’, N. Thalassinos”. “Departmenr of Psychiatry, bDepartment Evangelismos
of Biochemistry, and ‘Department General Hospital, Athens, Greece
of Endocrinology,
Risperidone has been in use for some time in the treatment of psychotic
patients, based primarily on data derived from short-term usage of the drug. There exists however only insuflicient information correlating levels of the medication with clinical response, extrapyramidal sideeffects (EPS) or ptolactin (PRL) levels over periods longer than 8 weeks. To assess this, we enrolled 25 DSM-IV schizophrenic patients, mainly of recent onset, in a prospective study using risperidone 6-16 mglday. Five patients dropped out because of exacerbation (n=l) or minimal improvement (n=3) of psychotic symptoms or occurrence of severe akathisia (n=l). In the 20 remaining patients (14 men, 6 women; mean age 27.127.95 years) we investigated: (1) clinical response, as estimated by Positive and Negative Syndrome Scale (PANSS). Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (C.G.I.)-Severity of Illness and Improvement and (2) EPS by Bxtrapyramidal Symptoms Rating Scale (ESRS) at baseline and at 8 and 16 weeks of treatment; (3) sum of risperidone and its metabolite, 9-OH-risperidone, plasma levels by RIA and (4) plasma PRL levels by IRMA at 8 and 16 weeks of treatment. An overall score reduction in alI scales was observed over time. Twelve patients (60%) showed clinical improvement at 8 weeks and 17 (85%) at 16 weeks (responders as defined by Kane et al., 1988). All responders required a lower daily dose than non-responders (statistically significant at p
I B-74
The antioxidant status of saliva and blood plasma in depression
A.I. L&ash, V.G. Zaika, N.P. Milutina, A.O. Kucherenko. The Depanment of Biochemistry, Rostov State University, B. Sadovay, 105, 344006. The Depamnent of Psychiatry, Rostov State Medical Vniversify, Nakhichevansci, 31, 344022, Rostov-on-Don, Russia The aim of present work is to estimate the possibility of saliva application
for the antioxidant status of depressive states. The activity of antioxidant systems was studied in the blood plasma and the saliva of 23 depressive patients (according to ICD-10: F 32 depressive episode; F 33 recurrent depressive disorders) in comparison with group of practically healthy donors (12 peoples). The total estimation of the seriousness of depression state was evaluated by Hamilton Scale (HRDS). Extracellular superoxidedismutase (SOD) activity was increased in saliva and blood plasma by 83% and 95% correspondingly, catalase activity-79% and 74%. total peroxidase activity (TPA) by 221% and 106%. Ceruloplasmine activity was increased in the saliva of depressive patients by 77%. The level of middle mass molecules (MMM) having antioxidant properties was rose by nucleotide fraction component (254 nm) as well as by peptide fraction component (280 nm). Perhaps these alterations may be regarded as partial compensation of the increase of free radical process level by 28% in saliva and by 22% in blood plasma (according to light sum of Fe*+-induced hemiluminescence). After antidepressant treatment (amitriptyline, imizin, fluoxetine, coaxil) we discovered the decrease of HDRS sum 2.5-3 times in the all studies groups of depressive patients. The positive dynamics was noted for many investigated parameters, however only cat&se activity in blood plasma and saliva; SOD activity in saliva and also the peptive fraction of MMM (280 nm) in blood plasma amounted to control values.